* Reata Pharmaceuticals, Inc. receives orphan drug designation for omaveloxolone for the treatment of friedreich’s ataxia

* Reata Pharmaceuticals Inc - U.S. Food and Drug Administration granted orphan drug designation to omaveloxolone for treatment of friedreich's ataxia Source text for Eikon: Further company coverage: